Ivacaftor (VX-770)

Ivacaftor (VX-770) is a potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively.

Price Stock Quantity  
In DMSO USD 112 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
USD 2470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Ivacaftor (VX-770) Chemical Structure

Ivacaftor (VX-770) Chemical Structure
Molecular Weight: 392.49

Validation & Quality Control

Customer Reviews(2)

Quality Control & MSDS

Related Compound Libraries

Ivacaftor (VX-770) is available in the following compound libraries:

Product Information

  • Compare CFTR Chemicals
    Compare CFTR Chemicals
  • Research Area

Product Description

Biological Activity

Description Ivacaftor (VX-770) is a potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively.
Targets G551D-CFTR F508del-CFTR
IC50 100 nM 25 nM [1]
In vitro Ivacaftor (10 μM) significantly increases the forskolin-stimulated Cl- secretion (IT) by ~4-fold with an EC50 of 100 nM in the recombinant Fisher rat thyroid (FRT) cells expressing G551D gating mutation of CFTR, and by ~6-fold with an EC50 of 25 nM in the recombinant cells expressing temperature-corrected F508del processing mutation of CFTR. Consistent with the increases in the forskolin-stimulated IT, Ivacaftor (10 μM) increases the open probability (Po) of G551D-, F508del-, and wild-type CFTR by ~6-fold, ~5-fold and ~2-fold, respectively, indicating that Ivacaftor acts directly on CFTR to increase its gating activity. In primary cultured human CF bronchial epithelia (HBE) carrying the G551D and F508del CFTR mutations, Ivacaftor (10 μM) potently increases the forskolin-stimulated IT by ~10-fold from 5% to a maximum level of 48% of that measured in non-CF HBE, with an EC50 of 236 nM displaying ~70-fold more potency compared with the commonly used CFTR potentiator genistein, which has an EC50 of 16 μM. In HBE with F508del homozygous CFTR, Ivacaftor causes a significant increase in the forskolin-stimulated IT with an EC50 of 22 nM, to a less extent from 4% to 16% of non-CF HBE compared with the effect in G551D/F508del HBE. Due to CFTR potentiation, Ivacaftor inhibits excessive ENaC-mediated Na+ and fluid absorption with an IC50 of 43 nM, and decreases the amiloride response, resulting in an increase in the surface fluid and cilia beat frequency (CBF) in G551D/F508del HBE. [1]
In vivo
Features The first potent and orally available CFTR potentiator to enter human clinical trials.

Protocol(Only for Reference)

Kinase Assay: [1]

Ussing Chamber Recordings The effect of Ivacaftor on CFTR-mediated Cl- secretion is characterized by measuring the CFTR-mediated IT in chambers using recombinant Fisher rat thyroid (FRT) cells expressing G551D, or F508del CFTR. Cells are grown on Costar Snapwell cell culture inserts maintained at 37 °C before recording. The cell culture inserts are mounted into an Ussing chamber to record IT in the voltage-clamp mode (Vhold = 0 mV). For FRT cells, the basolateral membrane is permeabilized with 360 μg/mL Nystatin and a basolateral to apical Cl- gradient is established. The basolateral bath solution contains 135 mM NaCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 2.4 mM K2HPO4, 0.6 mM KHPO4, 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (Hepes), and 10 mM dextrose (titrated to pH 7.4 with NaOH). The apical NaCl is replaced by equimolar Na+ gluconate (titrated to pH 7.4 with NaOH). The addition of a maximally effective concentration of forskolin (10 μM) is used to stimulate IT in the presence of various concentrations of Ivacaftor. All recordings are digitally acquired using Acquire and Analyze software. EC50 values are determined from the concentration-response curve of the increase in forskolin-stimulated IT after application of Ivacaftor.


Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT01784419 Not yet recruiting Cystic Fibrosis University of California, San Francisco 2013-10
NCT01937325 Not yet recruiting Cystic Fibrosis The Alfred 2013-10 Phase 4
NCT01931839 Enrolling by invitation Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation Vertex Pharmaceuticals Incorporated 2013-10 Phase 3
NCT01946412 Enrolling by invitation Cystic Fibrosis Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation 2013-12 Phase 3
NCT02015507 Not yet recruiting Cystic Fibrosis Vertex Pharmaceuticals Incorporated 2014-01 Phase 1

Chemical Information

Download Ivacaftor (VX-770) SDF
Molecular Weight (MW) 392.49


CAS No. 873054-44-5
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms N/A
Solubility (25°C) * In vitro DMSO 78 mg/mL (198 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

Preparing Stock Solutions

Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.39249 3.9249 7.8498 11.7747

Research Area

Customer Reviews (2)

Click to enlarge
Source Ivacaftor (VX-770) purchased from Selleck
Method Calcium signal recording
Cell Lines CHO-G551D cells
Concentrations 10 μM
Incubation Time
Results VX-770 reduced OAG Ca2+ influx ( Fig . A) by almost 70% whereas adding GPinh 5a to VX-770 increases OAG Ca2+ influx compared to VX-770 alone ( Fig. B).

Click to enlarge
Source Ivacaftor (VX-770) purchased from Selleck
Method Iodide efflux
Cell Lines CHO-G551D cells
Concentrations 10 μM
Incubation Time 0-8 min
Results The iodide efflux showed that VX-770 activates G551 D- CFTR channel and that OAG + VX-770 increased G551 D- CFTR activity by 58% ( Fig. C, D)

Product Citations (2)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related CFTR Chemicals

  • VX-661

    VX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.

  • CFTRinh-172

    CFTRinh-172 is a voltage-independent, selective CFTR inhibitor with Ki of 300 nM, showing no effects on MDR1, ATP-sensitive K+ channels, or a series of other transporters.

  • IOWH032

    IOWH032 is a synthetic CFTR inhibitor with IC50 of 1.01 μM in CHO-CFTR cell based assays. Phase 1/2.

  • Ataluren (PTC124)

    PTC124 (Ataluren) selectively induces ribosomal read-through of premature but not normal termination codons, with EC50 of 0.1 μM, may provide treatment for genetic disorders caused by nonsense mutations (e.g. CF caused by CFTR nonsense mutation). Phase 3.

    Features:Demonstrates oral bioavailability, and an appropriate safety toxicology profile.

  • VX-809 (Lumacaftor)

    VX-809 acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM. Phase 3.

    Features:Higher specificity and efficacy relative to other CFTR defect drugs.

  • Ivacaftor (VX-770)

    Ivacaftor (VX-770) is a potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively.

    Features:The first potent and orally available CFTR potentiator to enter human clinical trials.

  • Zosuquidar (LY335979) 3HCl

    Zosuquidar (LY335979) is a potent modulator of P-glycoprotein-mediated multi-drug resistance with Ki of 60 nM. Phase 3.

  • Omecamtiv mecarbil (CK-1827452)

    Omecamtivmecarbil (CK-1827452) is a specific cardiac myosinactivator and a clinical drug for left ventricular systolic heart failure. Phase 2.

  • Oligomycin A

    Oligomycin A is an inhibitor of ATP synthase, inhibits oxidative phosphorylation and all the ATP-dependent processes occurring on the coupling membrane of mitochondria.

  • Riluzole

    Riluzole is a drug used to treat amyotrophic lateral sclerosis.

Recently Viewed Items

Tags: buy Ivacaftor (VX-770) | Ivacaftor (VX-770) ic50 | Ivacaftor (VX-770) price | Ivacaftor (VX-770) cost | Ivacaftor (VX-770) solubility dmso | Ivacaftor (VX-770) purchase | Ivacaftor (VX-770) manufacturer | Ivacaftor (VX-770) research buy | Ivacaftor (VX-770) order | Ivacaftor (VX-770) mouse | Ivacaftor (VX-770) chemical structure | Ivacaftor (VX-770) mw | Ivacaftor (VX-770) molecular weight | Ivacaftor (VX-770) datasheet | Ivacaftor (VX-770) supplier | Ivacaftor (VX-770) in vitro | Ivacaftor (VX-770) cell line | Ivacaftor (VX-770) concentration | Ivacaftor (VX-770) nmr
Contact Us